Voretigen Neparvovec (2, reassessment) (Luxturna®) – Hereditary retinal dystrophy

Characteristics

Start date 01.04.2022
Resolution 15.09.2022 – active procedure
INN Voretigen Neparvovec
Brand name Luxturna®
Pharm. company Novartis Pharma GmbH
Therapeutic area Eye diseases ORPHAN
Reason for procedure Reassessment: G-BA limitation
Original resolution: Voretigen Neparvovec (17.10.2019)

Associated procedures



<< List of all resolutions